Rationale and study design of the GOREISAN for heart failure (GOREISAN-HF) trial: A randomized clinical trial
Hidenori Yaku(Kyoto University), Takeshi Kimura(Municipal Hirakata City Hospital), Yodo Tamaki(Tenri Hospital), Koichiro Kuwahara(Shinshu University), Jun Kitamura(Kobe Kaisei Hospital), Yukihito Sato(Hyogo Prefectural Amagasaki General Medical Center), Takao Kato(Juntendo University Hospital), Yasushi Sakata(Osaka University), Akihiro Isotani(Kokura Memorial Hospital), Kazuhisa Kaneda(Mitsubishi Kyoto Hospital), Kazuya Nagao(Nagaoka Red Cross Hospital), Yoshihisa Nakagawa(Shiga University of Medical Science), Takeshi Morimoto(Hyogo Medical University), Chisato Izumi(National Cerebral and Cardiovascular Center), Hirotaka Ezaki(National Defense Medical College Hospital), Takeshi Kitai, Hiromi Yamamoto(Tokyo Medical and Dental University), Takeshi Arita(Kyoto University), Ryusuke Nishikawa(Shizuoka General Hospital), Satoaki Matoba(Kyoto Prefectural University of Medicine), Taketoshi Yamazaki(Rakuwakai Otowa Hospital), Yasutaka Inuzuka(Shiga Medical Center for Adults)
Cited by 21
Related Papers
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
|Nature Medicine|2022|889
Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases
|Nature Genetics|2020|599
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome
|Circulation Journal|2019|582
TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling
|Journal of Clinical Investigation|2006|554